Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 16/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.57 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.57 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263529 | 1.00 | SMYD3 (0.58) | SMYD3TAS1R3TAS1R1TAS1R2MEN1 | |
| SCHEMBL531505 | 0.93 | TAS1R3 (0.64) | TAS1R3TAS1R1TAS1R2MEN1ALDH1A1 | |
| SCHEMBL3456482 | 0.87 | SMYD3 (0.62) | SMYD3TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL20339993 | 0.87 | TAS1R3 (0.65) | TAS1R3TAS1R1TAS1R2MEN1ALDH1A1 | |
| SCHEMBL4259798 | 0.87 | SMYD3 (0.62) | SMYD3TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1711760 | 0.83 | TAS1R3 (0.57) | SMYD3TAS1R3TAS1R1TAS1R2MEN1 | |
| SCHEMBL3811649 | 0.82 | SMYD3 (0.68) | SMYD3MEN1KMT2A | |
| SCHEMBL27785151 | 0.80 | TAS1R3 (0.54) | TAS1R3TAS1R1TAS1R2MEN1ALDH1A1 | |
| SCHEMBL24359915 | 0.79 | NPC1 (0.71) | SMYD3MEN1KMT2A | |
| SCHEMBL3809790 | 0.79 | NPC1 (0.71) | SMYD3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101475528-A | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-07-08 | — | — | CN | disclosed |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| CN-100451004-C | Pyrimidine derivatives | ARENA PHARM INC (JP) | 2009-01-14 | — | — | CN | disclosed |
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| EP-1730122-A2 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-12-13 | — | — | EP | disclosed |
| CN-1798736-A | Novel quinoline, tetrahydroquinazoline and pyrimidine derivatives and methods of treatment related to their use | ARENA PHARM INC (JP) | 2006-07-05 | — | — | CN | disclosed |
| WO-2006035967-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR TREATING DISEASES RELATED TO MCH RECEPTOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| WO-2005095357-A2 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | WO | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | MCHR1, GPR119, MCHR2 | SMYD3 1323/4885TAS1R3 1130/4885TAS1R1 671/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | SMYD3 929/4885TAS1R3 768/4885TAS1R1 733/4885 |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | SMYD3 861/4885TAS1R3 1598/4885TAS1R1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.